SEC Filings
Argenx Commits $550 Million Upfront To Unnatural Products Deal — With Milestone Payments To Follow
The planned purchase adds peptide drug discovery to argenx’s antibody business, with potential oral and long-acting treatments.
argenx (ARGX) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
SEC Filings
The planned purchase adds peptide drug discovery to argenx’s antibody business, with potential oral and long-acting treatments.
Earnings
The CFO said Forte accounts for roughly half of the higher budget and that fuller guidance is coming at the JPMorgan conference.
Earnings
Argenx now expects combined R&D and SG&A spending of about $4 billion for 2026, including costs from the Forte Biosciences purchase.